carnitine has been researched along with Cirrhosis, Liver in 51 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine is potentially beneficial in patients with hepatic encephalopathy (HE)." | 9.51 | Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. ( Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Jung, YK; Kim, HS; Kim, HY; Kim, SE; Kim, SG; Lee, TH; Song, DS; Song, MJ; Yoon, EL, 2022) |
| "Data regarding the additional effect on the recurrence of hepatic encephalopathy (HE) after oral L-carnitine administration are scarce." | 9.51 | Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin. ( Hidaka, H; Iwasaki, S; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shao, X; Shibuya, A; Uojima, H; Wada, N, 2022) |
| "Objective In the present study, we prospectively examined the efficacy of levocarnitine in relieving symptoms of fatigue in patients with cirrhosis but without overt hepatic encephalopathy." | 8.02 | The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2021) |
| "The aim of this study was to determine whether oral L-carnitine administration reduces the blood ammonia concentration and number of hospital admissions for hepatic encephalopathy in patients with advanced cirrhosis." | 8.02 | L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. ( Fujita, K; Himoto, T; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oura, K; Sakamoto, T; Tadokoro, T; Takuma, K; Tani, J; Yoneyama, H, 2021) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 7.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| "The aim of this study was to elucidate the efficacy of the combination of L-carnitine and exercise, reported to prevent muscle wasting, for muscle complications (function, volume, and cramping) in patients with liver cirrhosis (LC) who received branched-chain amino acid supplementation." | 7.91 | Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation? ( Abe, M; Hiasa, Y; Hiraoka, A; Hirooka, M; Kiguchi, D; Matsuura, B; Michitaka, K; Ninomiya, T, 2019) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 7.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis." | 7.81 | L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. ( Asano, Y; Gondo, K; Hattori, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Matsuda, S; Nakakuki, N; Nakanishi, H; Suzuki, S; Takada, H; Takahashi, Y; Tamaki, N; Tsuchiya, K; Yasui, Y, 2015) |
| "The plasma level of carnitine, a co-factor involved in many metabolic reactions, is high in alcoholic liver cirrhosis, due to an increased amount of esterified carnitine." | 7.68 | Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. ( Amodio, P; Angeli, P; Gatta, A; Menon, F; Merkel, C, 1990) |
| "Carnitine is a vitamin-like substance that regulates lipid metabolism and energy production." | 6.66 | Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. ( Hanai, T; Imai, K; Shimizu, M; Shiraki, M; Suetugu, A; Takai, K, 2020) |
| "Sarcopenia has a negative impact on the prognosis of patients with liver cirrhosis (LC)." | 5.56 | Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2020) |
| "L-carnitine is potentially beneficial in patients with hepatic encephalopathy (HE)." | 5.51 | Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. ( Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Jung, YK; Kim, HS; Kim, HY; Kim, SE; Kim, SG; Lee, TH; Song, DS; Song, MJ; Yoon, EL, 2022) |
| "Data regarding the additional effect on the recurrence of hepatic encephalopathy (HE) after oral L-carnitine administration are scarce." | 5.51 | Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin. ( Hidaka, H; Iwasaki, S; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shao, X; Shibuya, A; Uojima, H; Wada, N, 2022) |
| "Hepatic encephalopathy is a major complication in patients with advanced cirrhosis and is associated with poor prognosis." | 5.48 | L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. ( Futsukaichi, Y; Kobayashi, S; Minemura, M; Sugiyama, T; Tajiri, K; Takahara, T; Yasumura, S, 2018) |
| "L-carnitine (L-C) is a naturally occurring substance in mammalian tissues that has recently been proposed as a therapeutic agent in hepatic encephalopathy and liver steatosis." | 5.07 | Acute systemic and splanchnic haemodynamic effects of L-carnitine in patients with cirrhosis. ( Albano, O; Antonica, G; Berardi, E; Ettorre, G; Godi, L; Lee, SS; Palasciano, G; Pugliese, D; Sabbà, C, 1992) |
| "In a group of liver cirrhosis (LC) patients subjected to a rectal ammonium overload test, the effect of L-carnitine on ammoniemia and on the type A numerical connection and star clock psychomotor tests has been evaluated." | 5.06 | Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. ( Aparisi, L; Bixquert, M; Castillo, M; del Olmo, JA; Rodrigo, JM; Serra, MA; Wassel, A, 1990) |
| "l-Carnitine supplementation is effective in improving muscle cramps, hyperammonemia, and hepatic encephalopathy in patients with cirrhosis." | 4.12 | Survival benefit of l-carnitine supplementation in patients with cirrhosis. ( Hanai, T; Imai, K; Katsumura, N; Miwa, T; Nishimura, K; Sakai, Y; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K, 2022) |
| "The aim of this study was to determine whether oral L-carnitine administration reduces the blood ammonia concentration and number of hospital admissions for hepatic encephalopathy in patients with advanced cirrhosis." | 4.02 | L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. ( Fujita, K; Himoto, T; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oura, K; Sakamoto, T; Tadokoro, T; Takuma, K; Tani, J; Yoneyama, H, 2021) |
| "Objective In the present study, we prospectively examined the efficacy of levocarnitine in relieving symptoms of fatigue in patients with cirrhosis but without overt hepatic encephalopathy." | 4.02 | The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2021) |
| "To evaluate the effects of L-carnitine on impaired brain function in patients with liver cirrhosis." | 3.96 | Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kubota, Y; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Nakanishi, K; Noda, T; Okada, M; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wan, W; Yamashita, K; Yasui, Y, 2020) |
| "Carnitine fraction levels were positively correlated with liver cirrhosis stage, particularly, long-chain acylcarnitines." | 3.96 | Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients. ( Fukusima, M; Haraguchi, M; Kobayashi, H; Miuma, S; Miyaaki, H; Nakao, K; Sasaki, R, 2020) |
| "The aim of this study was to elucidate the efficacy of the combination of L-carnitine and exercise, reported to prevent muscle wasting, for muscle complications (function, volume, and cramping) in patients with liver cirrhosis (LC) who received branched-chain amino acid supplementation." | 3.91 | Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation? ( Abe, M; Hiasa, Y; Hiraoka, A; Hirooka, M; Kiguchi, D; Matsuura, B; Michitaka, K; Ninomiya, T, 2019) |
| " In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status." | 3.91 | Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019) |
| "We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis." | 3.81 | L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. ( Asano, Y; Gondo, K; Hattori, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Matsuda, S; Nakakuki, N; Nakanishi, H; Suzuki, S; Takada, H; Takahashi, Y; Tamaki, N; Tsuchiya, K; Yasui, Y, 2015) |
| " L-Carnitine is a vitamin-like substance and several reports have described the usefulness of L-carnitine supplementation in cases of cirrhosis, with confirmed effectiveness against refractory hepatic encephalopathy." | 3.81 | Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. ( Hasegawa, H; Ishihara, T; Iwasa, M; Kobayashi, Y; Mifuji-Moroka, R; Sekoguchi-Fujikawa, N; Sugimoto, R; Takei, Y; Tanaka, H; Yoshikawa, K, 2015) |
| "The plasma level of carnitine, a co-factor involved in many metabolic reactions, is high in alcoholic liver cirrhosis, due to an increased amount of esterified carnitine." | 3.68 | Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. ( Amodio, P; Angeli, P; Gatta, A; Menon, F; Merkel, C, 1990) |
| "Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo." | 3.11 | Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. ( Abraldes, JG; Alessandria, C; Beuers, U; Campion, D; Caraceni, P; Carol, M; Davis, MM; de Wit, K; Durand, F; Francoz, C; Ginès, P; Jiménez, C; Juanola, A; Kamath, PS; Kazankov, K; Lozano, JJ; Ma, AT; Mookerjee, RP; Morales-Ruiz, M; Napoleone, L; Piano, S; Pose, E; Sidorova, J; Solà, E; Tonon, M; Trebicka, J; Uschner, F; Vargas, V; Watson, H; Zaccherini, G, 2022) |
| "Carnitine is a conditionally necessary vitamin that aids in energy creation and fatty acid metabolism." | 3.01 | Biomedical role of L-carnitine in several organ systems, cellular tissues, and COVID-19. ( Al-Dhuayan, IS, 2023) |
| "Carnitine is a vitamin-like substance that regulates lipid metabolism and energy production." | 2.66 | Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. ( Hanai, T; Imai, K; Shimizu, M; Shiraki, M; Suetugu, A; Takai, K, 2020) |
| "Minimal hepatic encephalopathy (mHE) is common among patients with cirrhotic liver disease and causes significant morbidity and mortality." | 2.52 | Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy. ( Direkze, S; Jalan, R, 2015) |
| "Sarcopenia has a negative impact on the prognosis of patients with liver cirrhosis (LC)." | 1.56 | Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder." | 1.56 | L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. ( Codella, R; Luzi, L; Mollica, G; Montesano, A; Senesi, P; Terruzzi, I; Vacante, F, 2020) |
| "Hepatic encephalopathy is a major complication in patients with advanced cirrhosis and is associated with poor prognosis." | 1.48 | L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. ( Futsukaichi, Y; Kobayashi, S; Minemura, M; Sugiyama, T; Tajiri, K; Takahara, T; Yasumura, S, 2018) |
| "Liver fibrosis is a reversible wound-healing response that occurs following liver injury." | 1.40 | Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. ( Bahcecioglu, IH; Demiroren, K; Dogan, Y; Ilhan, S; Kocamaz, H; Ozercan, IH; Ustundag, B, 2014) |
| "Fifty pairs of liver cancer samples and matched normal tissues were collected from patients having hepatocellular carcinoma, including tumor tissues, adjacent noncancerous tissues, and distal noncancerous tissues, and 105 metabolites were filtered and identified from the tissue metabolome." | 1.39 | Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. ( Gao, P; Huang, Q; Lu, X; Tan, Y; Wang, H; Xu, G; Ye, G; Yin, P, 2013) |
| "Carnitine is an essential cofactor in the transfer of long-chain fatty acids across the inner mitochondrial membrane for oxidation." | 1.31 | Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. ( Aydogdu, S; Huseyinov, A; Selimoglu, MA; Yagci, RV, 2001) |
| "Carnitine metabolism was studied in 79 patients with chronic liver disease, including 22 patients with noncirrhotic liver disease and 57 patients with different types of cirrhosis (22 patients with hepatitis B- or C-associated cirrhosis, 15 patients with alcohol-induced cirrhosis, 15 patients with primary biliary cirrhosis [PBC], and 5 patients with cryptogenic cirrhosis), and compared with 28 control subjects." | 1.30 | Carnitine metabolism in patients with chronic liver disease. ( Krähenbühl, S; Reichen, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (13.73) | 18.7374 |
| 1990's | 6 (11.76) | 18.2507 |
| 2000's | 4 (7.84) | 29.6817 |
| 2010's | 20 (39.22) | 24.3611 |
| 2020's | 14 (27.45) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K | 2 |
| Fujita, M | 2 |
| Hayashi, M | 2 |
| Takahashi, A | 2 |
| Ohira, H | 2 |
| Pose, E | 1 |
| Solà, E | 1 |
| Lozano, JJ | 1 |
| Juanola, A | 1 |
| Sidorova, J | 1 |
| Zaccherini, G | 1 |
| de Wit, K | 1 |
| Uschner, F | 1 |
| Tonon, M | 1 |
| Kazankov, K | 1 |
| Jiménez, C | 1 |
| Campion, D | 1 |
| Napoleone, L | 1 |
| Ma, AT | 1 |
| Carol, M | 1 |
| Morales-Ruiz, M | 1 |
| Alessandria, C | 1 |
| Beuers, U | 1 |
| Caraceni, P | 1 |
| Francoz, C | 1 |
| Durand, F | 1 |
| Mookerjee, RP | 1 |
| Trebicka, J | 1 |
| Vargas, V | 1 |
| Piano, S | 1 |
| Watson, H | 1 |
| Abraldes, JG | 1 |
| Kamath, PS | 1 |
| Davis, MM | 1 |
| Ginès, P | 1 |
| Miwa, T | 1 |
| Hanai, T | 2 |
| Nishimura, K | 1 |
| Sakai, Y | 1 |
| Imai, K | 2 |
| Suetsugu, A | 1 |
| Takai, K | 2 |
| Shiraki, M | 3 |
| Katsumura, N | 1 |
| Shimizu, M | 2 |
| Yoon, EL | 1 |
| Ahn, SB | 1 |
| Jun, DW | 1 |
| Cho, YK | 1 |
| Song, DS | 1 |
| Jeong, JY | 1 |
| Kim, HY | 1 |
| Jung, YK | 1 |
| Song, MJ | 1 |
| Kim, SE | 1 |
| Kim, HS | 1 |
| Jeong, SW | 1 |
| Kim, SG | 1 |
| Lee, TH | 1 |
| Murata, K | 1 |
| Kaji, K | 1 |
| Nishimura, N | 1 |
| Enomoto, M | 1 |
| Fujimoto, Y | 1 |
| Takeda, S | 1 |
| Tsuji, Y | 1 |
| Fujinaga, Y | 1 |
| Takaya, H | 1 |
| Kawaratani, H | 1 |
| Namisaki, T | 1 |
| Akahane, T | 1 |
| Yoshiji, H | 2 |
| Sánchez-Quevedo, J | 1 |
| Ocampo-Rodríguez, E | 1 |
| Alvarez-Ayala, E | 1 |
| Rodríguez-López, A | 1 |
| Duarte-Vázquez, MA | 1 |
| Rosado, JL | 1 |
| Rodríguez-Fragoso, L | 1 |
| Al-Dhuayan, IS | 1 |
| Mollica, G | 1 |
| Senesi, P | 1 |
| Codella, R | 1 |
| Vacante, F | 1 |
| Montesano, A | 1 |
| Luzi, L | 1 |
| Terruzzi, I | 1 |
| Miyaaki, H | 2 |
| Kobayashi, H | 1 |
| Miuma, S | 1 |
| Fukusima, M | 1 |
| Sasaki, R | 1 |
| Haraguchi, M | 1 |
| Nakao, K | 1 |
| Suetugu, A | 1 |
| Nakanishi, H | 4 |
| Hayakawa, Y | 1 |
| Kubota, Y | 1 |
| Kurosaki, M | 3 |
| Osawa, L | 1 |
| Inada, K | 1 |
| Kirino, S | 1 |
| Yamashita, K | 1 |
| Sekiguchi, S | 1 |
| Okada, M | 1 |
| Wan, W | 1 |
| Higuchi, M | 1 |
| Takaura, K | 1 |
| Maeyashiki, C | 1 |
| Kaneko, S | 1 |
| Tamaki, N | 2 |
| Yasui, Y | 2 |
| Noda, T | 1 |
| Nakanishi, K | 1 |
| Tsuchiya, K | 2 |
| Itakura, J | 2 |
| Takahashi, Y | 2 |
| Izumi, N | 3 |
| Tani, J | 1 |
| Morishita, A | 1 |
| Sakamoto, T | 1 |
| Takuma, K | 1 |
| Nakahara, M | 1 |
| Fujita, K | 1 |
| Oura, K | 1 |
| Tadokoro, T | 1 |
| Mimura, S | 1 |
| Nomura, T | 1 |
| Yoneyama, H | 1 |
| Kobara, H | 1 |
| Himoto, T | 1 |
| Masaki, T | 1 |
| Kubota, K | 1 |
| Uojima, H | 1 |
| Shao, X | 1 |
| Iwasaki, S | 1 |
| Hidaka, H | 1 |
| Wada, N | 1 |
| Nakazawa, T | 1 |
| Shibuya, A | 1 |
| Kako, M | 1 |
| Koizumi, W | 1 |
| Loomba, R | 1 |
| Kayali, Z | 1 |
| Noureddin, M | 1 |
| Ruane, P | 1 |
| Lawitz, EJ | 1 |
| Bennett, M | 1 |
| Wang, L | 1 |
| Harting, E | 1 |
| Tarrant, JM | 1 |
| McColgan, BJ | 1 |
| Chung, C | 1 |
| Ray, AS | 1 |
| Subramanian, GM | 1 |
| Myers, RP | 1 |
| Middleton, MS | 1 |
| Lai, M | 1 |
| Charlton, M | 1 |
| Harrison, SA | 1 |
| Tajiri, K | 1 |
| Futsukaichi, Y | 1 |
| Kobayashi, S | 1 |
| Yasumura, S | 1 |
| Takahara, T | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Hiraoka, A | 2 |
| Kiguchi, D | 1 |
| Ninomiya, T | 1 |
| Hirooka, M | 1 |
| Abe, M | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Michitaka, K | 2 |
| Iwasa, M | 2 |
| Karino, Y | 1 |
| Nakajima, T | 1 |
| Kawaguchi, T | 1 |
| Sawada, Y | 1 |
| Okita, K | 1 |
| Sakamoto, N | 1 |
| Suda, G | 1 |
| Morikawa, K | 2 |
| Ogawa, K | 1 |
| Enooku, K | 1 |
| Nakagawa, H | 1 |
| Fujiwara, N | 1 |
| Kondo, M | 1 |
| Minami, T | 1 |
| Hoshida, Y | 1 |
| Shibahara, J | 1 |
| Tateishi, R | 1 |
| Koike, K | 1 |
| Huang, Q | 1 |
| Tan, Y | 1 |
| Yin, P | 1 |
| Ye, G | 1 |
| Gao, P | 1 |
| Lu, X | 1 |
| Wang, H | 1 |
| Xu, G | 1 |
| Demiroren, K | 1 |
| Dogan, Y | 1 |
| Kocamaz, H | 1 |
| Ozercan, IH | 1 |
| Ilhan, S | 1 |
| Ustundag, B | 1 |
| Bahcecioglu, IH | 1 |
| Vidot, H | 1 |
| Carey, S | 1 |
| Allman-Farinelli, M | 1 |
| Shackel, N | 1 |
| Nakakuki, N | 1 |
| Takada, H | 1 |
| Matsuda, S | 1 |
| Gondo, K | 1 |
| Asano, Y | 1 |
| Hattori, N | 1 |
| Suzuki, S | 1 |
| Hosokawa, T | 1 |
| Mehta, SS | 1 |
| Fallon, MB | 1 |
| Direkze, S | 1 |
| Jalan, R | 1 |
| Nishikawa, H | 1 |
| Osaki, Y | 1 |
| Sugimoto, R | 1 |
| Ishihara, T | 1 |
| Sekoguchi-Fujikawa, N | 1 |
| Yoshikawa, K | 1 |
| Mifuji-Moroka, R | 1 |
| Tanaka, H | 1 |
| Kobayashi, Y | 1 |
| Hasegawa, H | 1 |
| Takei, Y | 1 |
| Elsemman, IE | 1 |
| Mardinoglu, A | 1 |
| Shoaie, S | 1 |
| Soliman, TH | 1 |
| Nielsen, J | 1 |
| Zheng, Z | 1 |
| Gelling, RW | 1 |
| Ganai, AA | 1 |
| Ganaie, IA | 1 |
| Verma, N | 1 |
| Farooqi, H | 1 |
| Malaguarnera, M | 2 |
| Huang, HJ | 1 |
| Zhang, AY | 1 |
| Cao, HC | 1 |
| Lu, HF | 1 |
| Wang, BH | 1 |
| Xie, Q | 1 |
| Xu, W | 1 |
| Li, LJ | 1 |
| Pistone, G | 1 |
| Astuto, M | 1 |
| Dell'Arte, S | 1 |
| Finocchiaro, G | 1 |
| Lo Giudice, E | 1 |
| Pennisi, G | 1 |
| Shi, J | 1 |
| Liu, S | 1 |
| Xie, WF | 1 |
| Lin, XH | 1 |
| Jiao, LL | 1 |
| Xu, GB | 1 |
| Tian, GS | 1 |
| Broquist, HP | 1 |
| Borum, PR | 1 |
| Krähenbühl, S | 2 |
| Reichen, J | 1 |
| Selimoglu, MA | 1 |
| Aydogdu, S | 1 |
| Yagci, RV | 1 |
| Huseyinov, A | 1 |
| Chen, SH | 1 |
| Lincoln, SD | 1 |
| Rudman, D | 2 |
| Sewell, CW | 1 |
| Ansley, JD | 1 |
| Pugliese, D | 1 |
| Sabbà, C | 1 |
| Ettorre, G | 1 |
| Berardi, E | 1 |
| Antonica, G | 1 |
| Godi, L | 1 |
| Palasciano, G | 1 |
| Lee, SS | 1 |
| Albano, O | 1 |
| Amodio, P | 1 |
| Angeli, P | 1 |
| Merkel, C | 1 |
| Menon, F | 1 |
| Gatta, A | 1 |
| del Olmo, JA | 1 |
| Castillo, M | 1 |
| Rodrigo, JM | 1 |
| Aparisi, L | 1 |
| Serra, MA | 1 |
| Wassel, A | 1 |
| Bixquert, M | 1 |
| Campillo, B | 1 |
| Chapelain, C | 1 |
| Bonnet, JC | 1 |
| Frisdal, E | 1 |
| Devanlay, M | 1 |
| Bouissou, P | 1 |
| Fouet, P | 1 |
| Wirquin, E | 1 |
| Atlan, G | 1 |
| Böhles, H | 1 |
| Matsuyama, H | 1 |
| Hasegawa, T | 1 |
| Kuroda, M | 1 |
| Chawla, RK | 1 |
| Berry, CJ | 1 |
| Kutner, MH | 1 |
| Böhmer, T | 1 |
| Rydning, A | 1 |
| Solberg, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis[NCT02856555] | Phase 2 | 127 participants (Actual) | Interventional | 2016-08-08 | Completed | ||
| Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis[NCT05724485] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02856555)
Timeframe: First Dose date up to last dose (Week 12) plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Firsocostat 5 mg | 70.6 |
| Firsocostat 20 mg | 71.4 |
| Placebo | 61.5 |
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
8 reviews available for carnitine and Cirrhosis, Liver
| Article | Year |
|---|---|
Biomedical role of L-carnitine in several organ systems, cellular tissues, and COVID-19.
Topics: Carnitine; COVID-19; Dietary Supplements; Heart Diseases; Humans; Liver Cirrhosis | 2023 |
Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis.
Topics: Cardiomyopathies; Carnitine; Dietary Supplements; Humans; Hyperammonemia; Liver; Liver Cirrhosis; Mu | 2020 |
Systematic review: the treatment of muscle cramps in patients with cirrhosis.
Topics: Albumins; Amino Acids, Branched-Chain; Carnitine; Humans; Liver Cirrhosis; Muscle Cramp; Propiopheno | 2014 |
Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
Topics: Accidental Falls; Ammonia; Carnitine; Cognition Disorders; Electroencephalography; Gastrointestinal | 2015 |
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.
Topics: Carcinoma, Hepatocellular; Carnitine; Electric Impedance; Fibrosis; Hand Strength; Hepatitis C, Chro | 2015 |
Carnitine derivatives: clinical usefulness.
Topics: Acetylcarnitine; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Cognition Disorders; Depres | 2012 |
Carnitine biosynthesis: nutritional implications.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Animals; Carnitine; Child; Child, Preschool; Female | 1982 |
Carnitine metabolism in chronic liver disease.
Topics: Animals; Carnitine; Chronic Disease; Fatty Liver; Fatty Liver, Alcoholic; Hepatitis, Viral, Human; H | 1996 |
7 trials available for carnitine and Cirrhosis, Liver
| Article | Year |
|---|---|
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.
Topics: Acute-On-Chronic Liver Failure; Carnitine; Humans; Kynurenine; Liver Cirrhosis; Metabolomics; Rifaxi | 2022 |
Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
Topics: Carnitine; Double-Blind Method; End Stage Liver Disease; Hepatic Encephalopathy; Humans; Liver Cirrh | 2022 |
Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.
Topics: Carnitine; Hepatic Encephalopathy; Hospitalization; Humans; Liver Cirrhosis; Rifamycins; Rifaximin | 2022 |
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Topics: Acetyl-CoA Carboxylase; Biomarkers; Carnitine; Double-Blind Method; Elasticity Imaging Techniques; F | 2018 |
L-Carnitine in the treatment of mild or moderate hepatic encephalopathy.
Topics: Ammonia; Carnitine; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Ma | 2003 |
Acute systemic and splanchnic haemodynamic effects of L-carnitine in patients with cirrhosis.
Topics: Adult; Aged; Blood Pressure; Carnitine; Female; Hemodynamics; Hepatic Encephalopathy; Humans; Liver | 1992 |
Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients.
Topics: Aged; Ammonia; Carnitine; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; | 1990 |
36 other studies available for carnitine and Cirrhosis, Liver
| Article | Year |
|---|---|
The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy.
Topics: Aged; Carnitine; Fatigue; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male | 2021 |
Survival benefit of l-carnitine supplementation in patients with cirrhosis.
Topics: Carnitine; Dietary Supplements; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Retrospective Studi | 2022 |
Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.
Topics: Animals; Carnitine; Lipopolysaccharides; Liver Cirrhosis; Muscle, Skeletal; Muscular Atrophy; Rats; | 2022 |
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats.
Topics: Animals; Carnitine; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fructose; Glucose; Glycogen | 2022 |
L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet.
Topics: Animals; Carnitine; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; Disease P | 2020 |
Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Surve | 2020 |
Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Ammonia; Carnitine; Female; Humans; Liver Cirrhosis; Male; Middle Ag | 2020 |
Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy.
Topics: Aged; Brain Diseases; Carnitine; Female; Humans; Liver Cirrhosis; Male; Prognosis; Retrospective Stu | 2020 |
L-carnitine reduces hospital admissions in patients with hepatic encephalopathy.
Topics: Ammonia; Carnitine; Hepatic Encephalopathy; Hospitals; Humans; Liver Cirrhosis | 2021 |
L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis.
Topics: Aged; Aged, 80 and over; Ammonia; Carnitine; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis | 2018 |
Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?
Topics: Aged; Amino Acids, Branched-Chain; Carnitine; Dietary Supplements; Electric Impedance; Exercise Ther | 2019 |
Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study.
Topics: Aged; Carnitine; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Male; | 2019 |
Nutrition is often ignored in management of chronic liver diseases.
Topics: Amino Acids, Branched-Chain; Carnitine; Energy Metabolism; Humans; Liver Cirrhosis; Malnutrition; Nu | 2019 |
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Carcinoma, Hepatocellular; Carnitine; Disease Progression; Female; Humans; | 2019 |
Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
Topics: Adult; Aged; Antioxidants; Betaine; Carcinoma, Hepatocellular; Carnitine; Citric Acid Cycle; Fatty A | 2013 |
Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis.
Topics: Acetylcysteine; Animals; Carnitine; Disease Models, Animal; Genistein; Liver Cirrhosis; Male; Rats; | 2014 |
L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis.
Topics: Carnitine; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Cirrhosis; Muscle Cramp; P | 2015 |
Muscle Cramps in Cirrhosis: A Moving Target.
Topics: Carnitine; Humans; Liver Cirrhosis; Muscle Cramp | 2015 |
[Antiviral effect of carnitine for chronic hepatitis or liver cirrhosis patients].
Topics: Antiviral Agents; Carnitine; Hepatitis B; Hepatitis C; Hepatitis, Chronic; Humans; Liver Cirrhosis | 2015 |
Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma.
Topics: Ablation Techniques; Aged; Aged, 80 and over; Albumins; Amino Acids, Branched-Chain; Ammonia; Carcin | 2015 |
Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.
Topics: Acyl Coenzyme A; Acyltransferases; Carcinoma, Hepatocellular; Carnitine; Chromosomes, Human, Pair 1; | 2016 |
Attenuation of Carbon Tetrachloride-Induced Hepatic Toxicity by a Dietary Supplement.
Topics: Alanine Transaminase; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Animals; Aspartate Aminotr | 2017 |
Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage.
Topics: Actins; Animals; Body Weight; Carnitine; Chronic Disease; Collagen Type I; Galactosamine; Gene Expre | 2016 |
Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients.
Topics: Adult; Amino Acids, Aromatic; Bile Acids and Salts; Bile Pigments; Carnitine; Case-Control Studies; | 2013 |
[L-carnitine in the treatment of liver diseases].
Topics: Animals; Carnitine; Fatty Liver; Hepatitis, Viral, Human; Humans; Liver Cirrhosis | 2005 |
[Significance of serum carnitine in patients with liver diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carnitine; Chronic Disease; Female; Hepatitis, Viral, Hu | 2006 |
Carnitine metabolism in patients with chronic liver disease.
Topics: Adult; Aged; Bilirubin; Carnitine; Chronic Disease; Humans; Liver Cirrhosis; Liver Diseases; Middle | 1997 |
Plasma and liver carnitine status of children with chronic liver disease and cirrhosis.
Topics: Adolescent; Adult; Carnitine; Child; Child, Preschool; Chronic Disease; Female; Hepatolenticular Deg | 2001 |
Increased serum carnitine concentration in renal insufficiency.
Topics: Adult; Blood Urea Nitrogen; Carnitine; Coronary Disease; Humans; Kidney Diseases; Liver Cirrhosis; M | 1977 |
Deficiency of carnitine in cachectic cirrhotic patients.
Topics: Adult; Cachexia; Carnitine; Diet; Female; Hospitalization; Humans; Liver Cirrhosis; Lysine; Male; Me | 1977 |
Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage.
Topics: Adult; Aged; Alcoholism; Carnitine; Female; gamma-Glutamyltransferase; Humans; Kidney; Liver; Liver | 1990 |
Hormonal and metabolic changes during exercise in cirrhotic patients.
Topics: Age Factors; Blood Glucose; Calorimetry, Indirect; Carnitine; Catecholamines; Eating; Exercise; Fatt | 1990 |
[When is parenteral carnitine administration indicated?].
Topics: Acidosis; Adult; Ammonia; Carnitine; Fat Emulsions, Intravenous; Humans; Infant, Newborn; Infant, Pr | 1986 |
[Determination of serum L-carnitine by an implication of Cobas Bio centrifugal analyzer and its clinical implication in health and disease].
Topics: Adult; Aged; Carnitine; Centrifugation; Colorimetry; Diabetes Mellitus; Female; Humans; Kidney Failu | 1988 |
Plasma concentrations of transsulfuration pathway products during nasoenteral and intravenous hyperalimentation of malnourished patients.
Topics: Adolescent; Adult; Aged; Amino Acids; Blood Proteins; Carnitine; Choline; Creatine; Cysteine; Entera | 1985 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |